Cambridge, MA - Clinical Research IO (CRIO), a Cambridge-based technology company that has developed the first eSource system built and marketed directly to clinical research sites, announced today that it will collaborate with ArisGlobal to streamline clinical research.
CRIO’s system replaces the paper forms used at many research sites with an interactive web and tablet-based application. Using the system, researchers are able to configure eSource templates, and capture data quickly and accurately. By digitizing the collection of source data by investigators and integrating with other solutions, the company offers sponsors improved data quality and streamlined workflows.
Under the collaboration effort between CRIO and ArisGlobal, data captured electronically in CRIO will integrate with ArisGlobal’s agCapture, an electronic data capture system, and its integrated CTMS solution, thus eliminating double data entry and source data verification, two activities that consume up to 20% of the total time spent on a clinical trial.
“This collaboration is an excellent example of the cross-vendor collaboration required to resolve challenges in clinical research,” said Phuc Truong, co-founder of CRIO. “With this integration, we can give principal investigators and their staff an extremely user-friendly interface to collect data in way that’s consistent with their workflows, and ArisGlobal can deliver their life science sponsors immediate access to accurate data that does not need source verification.”
“Integration with Clinical Research IO further ours mission of offering life sciences companies a full lifecycle solution to enhance data quality and streamline operations,” said David Laky, Vice President of ArisGlobal – Clinical Solutions. “Many of our clients are looking for a solution to take out cost and time while enhancing data quality, and through this collaboration, we can deliver exactly that solution.”
Clinical Research IO (CRIO)
CRIO is the leading eSource solution for clinical research sites. Since its launch in September, 2016, it has signed up 50 research sites, and is now deployed on over 60 studies. For more information, visit www.clinicalresearch.io.
ArisGlobal
ArisGlobal’s cloud-based solutions facilitate global drug development and regulatory compliance within the life sciences and healthcare industries. Its cloud platform supports the entire product life cycle including clinical development, regulatory affairs, safety and pharmacovigilance and medical communications. Visit arisglobal.com, or follow ArisGlobal on LinkedIn and Twitter.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.